Carfilzomib, Bendamustine, And Dexamethasone (Kbd) In Advanced Multiple Myeloma: The Emn09-Trial.
JOURNAL OF CLINICAL ONCOLOGY(2018)
Abstract
8019Background: Various new agents have been introduced recently to treat relapsed/refractory multiple myeloma (RRMM), yet the chronification of the disease requires additional options for patients (pts) in advanced stages. Here, effectiveness and tolerability are important. Many advanced pts have received little chemotherapy but may suffer from peripheral neuropathy (PN). Carfilzomib (K) is a potent novel proteasome inhibitor not inducing significant PN. K was combined with bendamustine (B) to achieve synergistic effects. KB with low-dose dexamethasone (d) was tested in RRMM pts in a phase 1/2 trial (NCT02056756). Methods: 63 RRMM pts with ≥2 lines of prior therapy received KBd. Therapy consisted of 8 28-day courses of B at 70 mg/m2 day 1,8; K at 27 mg/m2 (initially 20 mg/m2) day 1,2,8,9,15,16; d at 20 mg on every treatment day plus day 22,23. Responding pts received Kd maintenance every 14 days until PD. In the phase 1, a dose escalation in 6 pts to K at 36 mg/m2 was attempted but led to 2 dose limiting...
MoreTranslated text
Key words
advanced multiple myeloma,multiple myeloma,carfilzomib,dexamethasone
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined